Ginkgo Bioworks Holdings, Inc. (DNA) has been on a downward spiral lately with significant selling pressure. After declining 28.8% over the past four weeks, the stock looks well positioned for a trend ...

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

Ginkgo Bioworks (DNA) announced a new contract with the Advanced Research Projects Agency for Health, or ARPA-H, alongside partners Tritica ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Reshma Shetty co-founded Ginkgo Bioworks in 2008, a leading organism design company. As President and COO, she has overseen ...

Ginkgo Bioworks (DNA) reported its Q4 2024 earnings with a notable increase in cell engineering revenue but faced a significant ...

Part of the partners' plan is to use Plex's AI to identify potential new uses for existing treatments that can be used to ...

Ginkgo Bioworks and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems Under the $29 million ...

In this article, we are going to take a look at where Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique ...